Omeros (NASDAQ:OMER) Shares Down 3.1% – Here’s Why

Omeros Co. (NASDAQ:OMER)’s share price traded down 3.1% during trading on Monday . The stock traded as low as $10.61 and last traded at $10.86. 44,701 shares were traded during mid-day trading, a decline of 90% from the average session volume of 459,604 shares. The stock had previously closed at $11.21.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Rodman & Renshaw started coverage on Omeros in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 target price on the stock. D. Boral Capital started coverage on Omeros in a research note on Monday, December 23rd. They issued a “buy” rating and a $36.00 price target for the company. RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Omeros has an average rating of “Moderate Buy” and an average target price of $22.50.

Omeros Price Performance

The company has a market cap of $623.54 million, a PE ratio of -4.66 and a beta of 2.01. The business has a 50-day moving average of $8.32 and a 200 day moving average of $5.63.

Institutional Trading of Omeros

Hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets increased its position in Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 7,016 shares during the last quarter. MML Investors Services LLC increased its position in Omeros by 19.2% in the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 3,000 shares in the last quarter. SPC Financial Inc. purchased a new stake in Omeros in the third quarter worth about $77,000. SG Americas Securities LLC purchased a new stake in Omeros in the third quarter worth about $80,000. Finally, AQR Capital Management LLC purchased a new stake in Omeros in the second quarter worth about $105,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.